Barry L. Scott

Nessuna posizione attualmente

74 anni

Health Technology

Profilo

Barry L.
Scott was Vice President of Business Development for Biopure Corp.
from June 2002 to December 1, 2008.
From 1998 to 2002, he worked for Bristol-Myers Squibb Company, most recently as Vice President of International Business Development-Europe.
From 1996 to 1998, he was General Manager of Bristol-Myers Squibb Ltd.
Mr. Scott received a Diploma in Education from the University of Rhodesia and a Diploma in Marketing Management from the Institute of Marketing Management, South Africa.

Precedenti posizioni note di Barry L. Scott

Società	Posizione	Fine
Biopure Corp. Biopure Corp. Pharmaceuticals: MajorHealth Technology Biopure Corp. developed, manufactured and marketed oxygen therapeutics, a new class of pharmaceuticals that are administered intravenously to increase oxygen transport to the body's tissues. The company used patented and proprietary technology to develop and manufacture two products: Hemopure for human use, and Oxyglobin for veterinary use. It has developed Hemopure for the treatment of patients with cardiovascular ischemia. Oxyglobin, its veterinary product treated anemia in dogs, is the only oxygen therapeutic approved by the U.S. Food and Drug Administration and the European Commission. Biopure was founded in 1984 and was headquartered in Cambridge, MA.	Corporate Officer/Principal	01/12/2008

Vedi nel dettaglio l'esperienza di Barry L. Scott

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Barry L. Scott

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Aziende private	1
Biopure Corp. Biopure Corp. Pharmaceuticals: MajorHealth Technology Biopure Corp. developed, manufactured and marketed oxygen therapeutics, a new class of pharmaceuticals that are administered intravenously to increase oxygen transport to the body's tissues. The company used patented and proprietary technology to develop and manufacture two products: Hemopure for human use, and Oxyglobin for veterinary use. It has developed Hemopure for the treatment of patients with cardiovascular ischemia. Oxyglobin, its veterinary product treated anemia in dogs, is the only oxygen therapeutic approved by the U.S. Food and Drug Administration and the European Commission. Biopure was founded in 1984 and was headquartered in Cambridge, MA.	Health Technology